ISSN : 2146-3123
E-ISSN : 2146-3131

Characterization of 31 Patients with Riboflavin-Responsive Multiple acyl-CoA Dehydrogenase Deficiency
Jinru Zhang1, Jingzhe Han2, Yaye Wang1, Yue Wu1, Lixia Ma3, Xueqin Song1, Guang Ji1
1Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, China
2Department of Neurology, Harrison International Peace Hospital, Hengshui, China
3Department of Geriatrics, The Third Hospital of Shijiazhuang, Shijiazhuang, China
DOI : 10.4274/balkanmedj.galenos.2022.2022-1-127
Pages : 290-296

Aims: To evaluate the clinical, pathological, and genetic features of patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (RR-MADD).
Methods: Thirty-one patients with RR-MADD admitted to our hospital from January 2005 to November 2020 were enrolled, and their clinical data were collected. Pathological characteristics of the muscle tissue and possible pathogenic gene mutations were analyzed.
Results: The most common clinical features in all patients were symmetrical proximal muscle weakness. Laboratory examination revealed elevated levels of creatine kinase, homocysteine, and uric acid, acylcarnitines, and organic acid. The muscle biopsy revealed typical pathological changes like lipid deposition. Genetic analysis identified ETFDH mutations in 29 patients, among which one had homozygotes, 19 had compound heterozygotes, 7 had heterozygous mutations, and 2 had heterozygous mutations of both ETFDH and ETFA. Two patients had no pathogenic gene mutations. All patients were treated with riboflavin, and their symptoms improved, which was consistent with the diagnosis of RR-MADD.
Conclusion: The clinical manifestations and genetic test results of patients with RR-MADD are heterogeneous. Therefore, a comprehensive analysis of clinical, pathological, and genetic testing is essential for the early diagnosis of RR-MADD.

Viewed : 1802
Downloaded : 2144